{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:19:48Z","timestamp":1791883188699,"version":"4.3.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01KG1508"],"award-info":[{"award-number":["FKZ 01KG1508"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.euroneuro.2018.03.008","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T01:54:30Z","timestamp":1527126870000},"page":"659-674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"title":["Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6125-1466","authenticated-orcid":false,"given":"Marc","family":"Krause","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4011-1189","authenticated-orcid":false,"given":"Maximilian","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3448-9532","authenticated-orcid":false,"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chaimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.euroneuro.2018.03.008_bib1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.euroneuro.2014.11.003","article-title":"Present and future of developmental neuropsychopharmacology","volume":"25","author":"Arango","year":"2015","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib2","first-page":"45","article-title":"Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials","volume":"43","author":"Ardizzone","year":"2010","journal-title":"Psychopharmacol. Bull."},{"issue":"3","key":"10.1016\/j.euroneuro.2018.03.008_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00787-005-0515-2","article-title":"Antipsychotics in early onset Schizophrenia: systematic review and meta-analysis","volume":"15","author":"Armenteros","year":"2006","journal-title":"Eur. Child Adolesc. Psychiatry"},{"issue":"6 II","key":"10.1016\/j.euroneuro.2018.03.008_bib55","first-page":"886","article-title":"A double-blind controlled trial of loxapine and trifluoperazine in adolescent schizophrenia","volume":"27","author":"Bagadia","year":"1980","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3736\/jcim20060204","article-title":"Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology","volume":"4","author":"Bian","year":"2006","journal-title":"Zhong xi yi jie he xue bao = J. Chin. Integr. Med."},{"key":"10.1016\/j.euroneuro.2018.03.008_bib5","doi-asserted-by":"crossref","unstructured":"Blows, W.T., 2016. Biological Basis of Mental Health, 3rd ed., 1 online resource.","DOI":"10.4324\/9781315707167"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.03.008_bib6","article-title":"Review of the safety of second-generation antipsychotics: are they really \u201catypically\u201d safe for youth and adults?","volume":"14","author":"Briles","year":"2012","journal-title":"Prim. Care Companion CNS Disord."},{"issue":"6","key":"10.1016\/j.euroneuro.2018.03.008_bib7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"10.1016\/j.euroneuro.2018.03.008_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00004583-198705000-00012","article-title":"A North Dakota prevalence study of schizophrenia presenting in childhood","volume":"26","author":"Burd","year":"1987","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"7521","key":"10.1016\/j.euroneuro.2018.03.008_bib9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.euroneuro.2018.03.008_bib10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/1536867X1501500402","article-title":"Visualizing assumptions and results in network meta-analysis: the network graphs package","volume":"15","author":"Chaimani","year":"2015","journal-title":"Stata J."},{"issue":"10","key":"10.1016\/j.euroneuro.2018.03.008_bib11","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.euroneuro.2018.03.008_bib56","first-page":"785","article-title":"A double-blind comparison of haloperidol (Haldol) and thioridazine (Mellaril) in outpatient children","volume":"14","author":"Claghorn","year":"1972","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib13","series-title":"Statistical Power Analysis for the Behavioral Sciences","first-page":"459","author":"Cohen","year":"2013"},{"issue":"7-8","key":"10.1016\/j.euroneuro.2018.03.008_bib14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"issue":"6","key":"10.1016\/j.euroneuro.2018.03.008_bib15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"J. General. Intern. Med."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.03.008_bib16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"Int. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib57","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF01537988","article-title":"A double blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children","volume":"3","author":"Engelhardt","year":"1973","journal-title":"Journal of Autism and Childhood Schizophrenia"},{"issue":"11","key":"10.1016\/j.euroneuro.2018.03.008_bib58","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1176\/ajp.126.11.1670","article-title":"Comparison of haloperidol and fluphenazine in disturbed children","volume":"126","author":"Faretra","year":"1970","journal-title":"The American journal of psychiatry"},{"issue":"8","key":"10.1016\/j.euroneuro.2018.03.008_bib59","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/cap.2012.0068","article-title":"Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study","volume":"23","author":"Findling","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.euroneuro.2018.03.008_bib60","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/cap.2015.0027","article-title":"Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia","volume":"25","author":"Findling","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.euroneuro.2018.03.008_bib61","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2011.0092","article-title":"Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial","volume":"22","author":"Findling","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.euroneuro.2018.03.008_bib62","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2018.03.008_bib17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.03.008_bib18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1176\/ajp.134.3.302","article-title":"Weight reduction in schizophrenics by molindone","volume":"134","author":"Gardos","year":"1977","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib19","doi-asserted-by":"crossref","DOI":"10.1089\/cap.2016.0189","article-title":"Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-Week, randomized placebo-controlled study","author":"Goldman","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2018.03.008_bib63","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia","volume":"19","author":"Haas","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.euroneuro.2018.03.008_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40263-015-0308-1","article-title":"A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia","volume":"30","author":"Harvey","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib21","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. methods"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med."},{"issue":"4","key":"10.1016\/j.euroneuro.2018.03.008_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2007.0123","article-title":"A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders","volume":"18","author":"Jensen","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib65","doi-asserted-by":"crossref","unstructured":"Kaleda, V.G., Oleichik, I.V., Artioukh, V.V., Naddour, S.A., 2000. Risperidone vs haloperidol in the therapy of adolescent schizophrenia and schizoaffective disorders: International Journal of Neuropsychopharmacology (Abstracts of the XXIInd CINP Congress, Brussels, Belgium, July 9-13, 2000) 3, S99.","DOI":"10.1017\/S1461145700009998"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib24","first-page":"1603","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Kassebaum","year":"2016"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.euroneuro.2018.03.008_bib26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/eoid.12.4.655.23750","article-title":"Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic","volume":"12","author":"Keck","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib27","doi-asserted-by":"crossref","first-page":"f150","DOI":"10.1136\/bmj.f150","article-title":"Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance","volume":"346","author":"Kendall","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib28","first-page":"CD004027","article-title":"Antipsychotic medication for childhood-onset schizophrenia","volume":"3","author":"Kennedy","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2018.03.008_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","author":"Krause","year":"2018","journal-title":"Eur. Arch. psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.03.008_bib66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":"Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1016\/j.euroneuro.2018.03.008_bib67","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archpsyc.1996.01830120020005","article-title":"Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison","volume":"53","author":"Kumra","year":"1996","journal-title":"Arch Gen Psychiatry"},{"issue":"9896","key":"10.1016\/j.euroneuro.2018.03.008_bib30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.euroneuro.2018.03.008_bib31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib32","article-title":"Which are the most important first-generation antipsychotic drugs? Survey of international schizophrenia experts: abstracts from the 5th Biennial SIRS conference - poster abstracts","volume":"25","author":"Leucht","year":"2016","journal-title":"NPJ Schizophr."},{"issue":"96","key":"10.1016\/j.euroneuro.2018.03.008_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001512","article-title":"The emergence of genome-based drug repositioning","volume":"3","author":"Lussier","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.euroneuro.2018.03.008_bib68","first-page":"432","article-title":"Loxapine in adolescent schizophrenia: Current therapeutic research","volume":"28","author":"Malik","year":"1980","journal-title":"clinical and experimental"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/11585350-000000000-00000","article-title":"Management of schizophrenia in children and adolescents: focus on pharmacotherapy","volume":"71","author":"Masi","year":"2011","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.euroneuro.2018.03.008_bib35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jaac.2013.02.008","article-title":"Practice parameter for the assessment and treatment of children and adolescents with schizophrenia","volume":"52","author":"McClellan","year":"2013","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2018.03.008_bib69","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/cap.2006.16.393","article-title":"An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia","volume":"16","author":"Mozes","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.euroneuro.2018.03.008_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/0269881116642903","article-title":"Neuroscience-based nomenclature (NbN) for Journal of Psychopharmacology","volume":"30","author":"Nutt","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.euroneuro.2018.03.008_bib37","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.euroneuro.2014.05.012","article-title":"Where now for schizophrenia research?","volume":"24","author":"Nutt","year":"2014","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2018.03.008_bib38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch. General. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.03.008_bib39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"PR"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S2215-0366(17)30166-9","article-title":"Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial","author":"Pagsberg","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.03.008_bib41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaac.2016.12.013","article-title":"Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis","volume":"56","author":"Pagsberg","year":"2017","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2018.03.008_bib70","first-page":"99","article-title":"A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients","volume":"19","author":"Pool","year":"1976","journal-title":"Curr Ther Res Clin Exp"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.03.008_bib71","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1176\/ajp.141.3.440","article-title":"Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents","volume":"141","author":"Realmuto","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res. Synth. Methods"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.euroneuro.2018.03.008_bib44","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib72","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaac.2014.11.009","article-title":"Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study","volume":"54","author":"Savitz","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib45","series-title":"The Depressed Child and Adolescent","first-page":"292","article-title":"Psychopharmacology of depressive states in childhood and adolescence","author":"Schulz","year":"2001"},{"issue":"7","key":"10.1016\/j.euroneuro.2018.03.008_bib73","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","article-title":"Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison","volume":"63","author":"Shaw","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2018.03.008_bib74","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study","volume":"165","author":"Sikich","year":"2008","journal-title":"The American journal of psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2018.03.008_bib75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.euroneuro.2018.03.008_bib76","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.biopsych.2011.06.021","article-title":"A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents","volume":"70","author":"Singh","year":"2011","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib77","first-page":"183","article-title":"Haloperidol in schizophrenic children: early findings from a study in progress","volume":"28","author":"Spencer","year":"1992","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib46","doi-asserted-by":"crossref","first-page":"f185","DOI":"10.1136\/bmj.f185","article-title":"Early interventions to prevent psychosis: systematic review and meta-analysis","volume":"346","author":"Stafford","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib47","doi-asserted-by":"crossref","first-page":"e0117166","DOI":"10.1371\/journal.pone.0117166","article-title":"Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis","volume":"10","author":"Stafford","year":"2015","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.euroneuro.2018.03.008_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/YIC.0b013e3283320511","article-title":"A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents","volume":"25","author":"Swadi","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib48","series-title":"Psychosis and Schizophrenia in Children and Young People: Recognition and Management","first-page":"508","author":"The British Psychological Society","year":"2016"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.03.008_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1600-0447.1996.tb09847.x","article-title":"Schizophrenia with childhood and adolescent onset?: a nationwide register-based study","volume":"94","author":"Thomsen","year":"1996","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2018.03.008_bib80","first-page":"559","volume":"24","author":"Versiani","year":"1978","journal-title":"Double blind comparison between loxapine and haloperidol in the treatment of adolescent schizophrenic patients: Current Therapeutic Research Clinical and Experimental"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib50","series-title":"Mental Health: New Understanding, New Hope","author":"Weltgesundheitsorganisation","year":"2002"},{"issue":"4","key":"10.1016\/j.euroneuro.2018.03.008_bib51","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J."},{"issue":"2","key":"10.1016\/j.euroneuro.2018.03.008_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res. Synth. Methods"},{"issue":"9","key":"10.1016\/j.euroneuro.2018.03.008_bib81","first-page":"482","article-title":"A comparative study of thiothixene and trifluoperazine in childhood schizophrenia","volume":"9","author":"Wolpert","year":"1967","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.euroneuro.2018.03.008_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1745-6215-10-46","article-title":"Randomized trials published in some Chinese journals: how many are randomized?","volume":"10","author":"Wu","year":"2009","journal-title":"Trials"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18300713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18300713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T16:07:23Z","timestamp":1656864443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X18300713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0924977X18300713"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.03.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}